PredilifeXPAR:ALPRE -4.55%32 Net Margin % is -225.79% as of Dec. 2025. GuruFocus rates XPAR:ALPRE with a GF Score™ of 32/100 and a GF Value™ of €18.98 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Predilife ranks worse than 87.25% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Predilife's Net Income for the
six
months ended in Dec. 2025 was €-1.64 Mil. Predilife's Revenue for the
six
months ended in Dec. 2025 was €0.73 Mil. Therefore, Predilife's net margin for the quarter that ended in Dec. 2025 was -225.79%.
The historical rank and industry rank for Predilife's Net Margin % or its related term are showing as below:
XPAR:ALPRE'
s Net Margin % Range Over the Past 10 Years
Min: -8408 Med: -1326.1 Max: 32140.29
Current: -315.3
XPAR:ALPRE's Net Margin % is ranked worse than 87.25% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.56
vs XPAR:ALPRE: -315.30
Predilife (XPAR:ALPRE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Predilife Net Margin % Related Terms
Predilife Net Margin % Historical Data
* Premium members only.
The historical data trend for Predilife's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALPRE vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Predilife's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predilife Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Predilife's Net Margin % distribution charts can be found below:
* The bar in red indicates where Predilife's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Predilife (XPAR:ALPRE) has a Net Margin % of -225.79% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Predilife and its competitors. According to the industry distribution chart, Predilife ranks #178 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 87.3%.
Is Predilife's Net Margin % too high?
Predilife's current Net Margin % is -225.79%. Based on the distribution chart, Predilife ranks #178 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Predilife has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Predilife's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Predilife ranks #178 out of 204 companies for Net Margin %. This places Predilife in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Predilife and its competitors. Predilife's current Net Margin % is -225.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predilife stock overvalued right now?
Based on GuruFocus' analysis, Predilife (XPAR:ALPRE) is currently considered Possible Value Trap. The stock's GF Value™ is €18.98, compared to a current price of €2.10 — trading 88.9% below its estimated fair value. The current Net Margin % is -225.79%. Predilife's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Predilife (XPAR:ALPRE), the current Net Margin % is -225.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Predilife (XPAR:ALPRE) Overvalued in 2026?
Based on GuruFocus' analysis, Predilife stock appears to be undervalued.
The current stock price of €2.10 is trading 88.9% below its estimated GF Value™ of €18.98.
GuruFocus considers Predilife to be Possible Value Trap.
Key valuation signals for XPAR:ALPRE:
Net Margin %: -225.79%
GF Value™: €18.98 vs. price of €2.10 (88.9% below fair value)
No single metric tells the full story. See the XPAR:ALPRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Predilife SA develops solutions for predictive medicine, combining medical techniques (genetic tests, medical imaging) and mathematical models with a large amount of statistical data, which allows each individual to define their risk profile for the occurrence of various serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.
32GF Score
Get the complete analysis for XPAR:ALPRE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALPRE has been successfully added to your 
